Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422695 | 0.81 | SLC2A1 (0.58) | SLC2A1TSHRNPSR1ALDH1A1LMNA | |
| SCHEMBL11272357 | 0.80 | SLC2A1 (0.49) | SLC2A1TSHRMAOAHTR3AHRH3 | |
| SCHEMBL3567044 | 0.80 | SLC6A4 (0.59) | SLC2A1TSHRMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL7061665 | 0.80 | SLC2A1 (0.56) | SLC2A1TSHRCYP2D6MAPK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3750296 | 0.79 | SLC2A1 (0.56) | SLC2A1TSHRNPSR1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11535429 | 0.78 | SLC2A1 (0.55) | SLC2A1TSHRCYP2D6MAPK1ALDH1A1 | |
| SCHEMBL5356846 | 0.78 | SLC2A1 (0.54) | SLC2A1NPSR1ALDH1A1LMNATDP1 | |
| SCHEMBL8809913 | 0.77 | CA12 (0.57) | SLC2A1TSHRMAOAMAPK1ALDH1A1 | |
| SCHEMBL3838326 | 0.77 | SLC2A1 (0.53) | SLC2A1TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL1808815 | 0.76 | CYP3A4 (0.55) | TSHRMAOAMAPK1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084089-A1 | Unique and Selective Targeting of CDK Activity in Aggressive Carcinomas | UNIVERSITY OF WINDSOR (CA) | 2025-03-13 | — | — | US | disclosed |
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| US-7638523-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-12-29 | — | — | US | disclosed |
| US-7638523-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-12-29 | — | — | US | disclosed |
| US-7638523-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-12-29 | — | — | US | disclosed |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2009-10-22 | — | — | US | disclosed |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2009-10-22 | — | — | US | disclosed |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2009-10-22 | — | — | US | disclosed |
| US-7592349-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-09-22 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| WO-2007038669-A2 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038669-A2 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2007-04-05 | — | — | WO | disclosed |
| EP-1442025-B1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2007-03-07 | — | — | EP | disclosed |
| CN-1571774-A | Pyrimidinones as melanin concentrating hormone receptor 1 | SMITHKLINE BEECHAM PLC (GB) | 2005-01-26 | — | — | CN | disclosed |
| US-20040220404-A1 | Pyrimidinones as melanin concentrating hormone receptor 1 | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-11-04 | — | — | US | disclosed |
| EP-1442025-A1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003033476-A1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
| US-4906634-A | Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents | SCHERING A.G. (DE) | 1990-03-06 | — | — | US | disclosed |
| EP-0332570-A2 | Novel-N-(4-(Aminosubstituted)phenyl) methanesulfonamides and their use as cardiovascular agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084089-A1 | Unique and Selective Targeting of CDK Activity in Aggressive Carcinomas | CDK4, CDK3, CDKN1A | SLC2A1 4664/4885TSHR 3779/4885MAOA 3389/4885 |
| US-20040220404-A1 | Pyrimidinones as melanin concentrating hormone receptor 1 | MC1R, MCHR1, MCHR2 | SLC2A1 843/4885TSHR 33/4885MAOA 479/4885 |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | SLC2A1 3337/4885TSHR 3111/4885MAOA 395/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | SLC2A1 3337/4885TSHR 3111/4885MAOA 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.